Stocksigma LogoStocksigma Logo

Shelter Pharma Reports H1 FY27 Performance and Growth Roadmap

For the half year ended 30th Sep'26, Shelter Pharma posted a 35.6% YoY revenue increase to Rs 451.3 mn, driven by balanced growth across human health (Rs

Shelter Pharma Reports H1 FY27 Performance and Growth Roadmap

Shelter Pharma Ltd · Financial Result · 07 Nov 2026, 11:13 pm

Shelter Pharma Reports H1 FY27 Performance and Growth Roadmap For the half year ended 30th Sep'26, Shelter Pharma posted a 35.6% YoY revenue increase to Rs 451.3 mn, driven by balanced growth across human health (Rs 222.6 mn) and animal health (Rs 228.7 mn). EBITDA grew 17.9% YoY to Rs 73.8 mn, while PAT rose 15.4% YoY to Rs 51.9 mn with an 11.5% margin. The company reaffirmed FY27 guidance of 35–40% revenue growth and announced plans to invest Rs 120–150 mn in a second plant to achieve a Rs 2,000 mn revenue target by FY30.

Original exchange filing (PDF)

More announcements from Shelter Pharma Ltd

All Shelter Pharma Ltd announcements